

Massimo Massaia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2404585/publications.pdf>

Version: 2024-02-01

189
papers

6,767
citations

53660

45
h-index

69108

77
g-index

190
all docs

190
docs citations

190
times ranked

8274
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
2	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients. <i>Blood Cancer Journal</i> , 2022, 12, 8.	2.8	5
3	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	3
4	Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1066-1071.	0.2	1
5	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	1.2	16
6	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
7	Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment. <i>Medicina (Lithuania)</i> , 2021, 57, 1104.	0.8	3
8	CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. <i>Scientific Reports</i> , 2021, 11, 21230.	1.6	8
9	The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report. <i>Blood</i> , 2021, 138, 4684-4684.	0.6	3
10	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	0
11	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 80-89.	2.3	14
12	HIF-1 α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	1.7	39
13	Anticancer innovative therapy: Highlights from the ninth annual meeting. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 1-9.	3.2	0
14	Immunomodulatory and clinical effects of daratumumab in cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e28-e32.	1.2	13
15	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
16	Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. <i>Journal of Medical Case Reports</i> , 2020, 14, 75.	0.4	6
17	Metabolic approaches to rescue antitumor V gamma 9V delta 2 T-cell functions in myeloma. <i>Frontiers in Bioscience - Landmark</i> , 2020, 25, 69-105.	3.0	4
18	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	0.6	1

#	ARTICLE	IF	CITATIONS
19	A Position Paper on IgM-Enriched Intravenous Immunoglobulin Adjunctive Therapy in Severe Acute Bacterial Infections: The TO-PIRO SCORE Proposal. <i>New Microbiologica</i> , 2019, 42, 176-180.	0.1	3
20	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
21	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD ⁺ . <i>Oncolmmunology</i> , 2018, 7, e1458809.	2.1	59
22	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. <i>British Journal of Haematology</i> , 2018, 181, 693-695.	1.2	1
23	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Oncolmmunology</i> , 2018, 7, e1341032.	2.1	11
24	V β 9V α 2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. <i>Frontiers in Oncology</i> , 2018, 8, 508.	1.3	15
25	Increasing intratumor C/EBP- β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 286.	3.5	32
26	Regulation of HIF-1 β in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.2	0
27	ABCA1, apoA-I, and BTN3A1: A Legitimate M ϕ age Δ Trois in Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1246.	2.2	16
28	V β 9V α 2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. <i>Frontiers in Immunology</i> , 2018, 9, 1492.	2.2	21
29	Abstract 2122: Induction of structural and functional effects of myeloma cells after daratumumab treatment. , 2018, , .		1
30	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	1.7	9
31	A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). <i>Hematological Oncology</i> , 2017, 35, 426-427.	0.8	0
32	The ATP-binding cassette transporter A1 regulates phosphoantigen release and V β 9V α 2 T cell activation by dendritic cells. <i>Nature Communications</i> , 2017, 8, 15663.	5.8	57
33	A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility. <i>Diagnostics</i> , 2017, 7, 57.	1.3	11
34	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	0.8	13
35	The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S42.	0.2	0
36	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq0 0 0 ggBT /Over/lock 10 Tf		0/0

#	ARTICLE	IF	CITATIONS
37	Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 2059-2059.	0.6	1
38	A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies. <i>Blood</i> , 2016, 128, 2183-2183.	0.6	1
39	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.	0.6	0
40	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. <i>Blood</i> , 2016, 128, 3469-3469.	0.6	0
41	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and $\hat{V}^{\hat{3}}\hat{V}^{\hat{2}}$ T-Cell Activation By Dendritic Cells. <i>Blood</i> , 2016, 128, 3709-3709.	0.6	0
42	HIF-1 $\hat{\pm}$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	0.6	0
43	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
44	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504.	1.7	22
45	Anergic bone marrow $\hat{V}^{\hat{3}}\hat{V}^{\hat{2}}$ T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. <i>Oncolmunology</i> , 2015, 4, e1047580.	2.1	58
46	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015, 6, 29833-29846.	0.8	33
47	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , 2015, 126, 2925-2925.	0.6	0
48	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab <i>versus</i> fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	1.2	30
49	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	2.0	104
50	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2014, 99, e159-e161.	1.7	4
51	The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. <i>Haematologica</i> , 2014, 99, 1605-1610.	1.7	27
52	The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 833-833.	0.6	0
53	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3300-3300.	0.6	0
54	Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells. <i>Oncolmunology</i> , 2013, 2, e25770.	2.1	20

#	ARTICLE	IF	CITATIONS
55	Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule. <i>Molecular Medicine</i> , 2013, 19, 99-108.	1.9	58
56	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2013, 122, 4177-4177.	0.6	2
57	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e60975.	1.1	49
58	Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2013, 148, 453-63.	0.8	4
59	Aminobisphosphonates, statins and the mevalonate pathway: a cross-road to fine-tune the activation of NK and V β 9V α 2 T cells. <i>IBMS BoneKEy</i> , 2012, 9, .	0.1	3
60	Dysfunctional V β 9V α 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	0.6	51
61	Human γ Î<sc>T</sc>â€œcell responses in infection and immunotherapy: Common mechanisms, common mediators?. <i>European Journal of Immunology</i> , 2012, 42, 1668-1676.	1.6	53
62	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	0.8	28
63	Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2898-2898.	0.6	0
64	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 3881-3881.	0.6	0
65	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012, 120, 3878-3878.	0.6	0
66	2.28 Identification by Serological Proteome Analysis (SERPA) of Novel Tumor Associated Antigens in Chronic Lymphocytic Leukemia (CLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S176-S177.	0.2	0
67	2.37 Accelerated Activity of the Mevalonate Pathway Supports the Immune Escape and Multidrug-Resistance Phenotype of IGHV Unmutated Chronic Lymphocytic Leukemia Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S182.	0.2	0
68	5.9 Bendamustine and Alemtuzumab Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia: Interim Report of the Italian Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S247-S248.	0.2	0
69	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	3.3	61
70	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011, 117, 6721-6727.	0.6	113
71	V β 9V α 2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2419-2432.	2.4	35
72	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V β 9V α 2 T Cells, γ Î CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. <i>Journal of Immunology</i> , 2011, 187, 1578-1590.	0.4	77

#	ARTICLE	IF	CITATIONS
73	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	0.6	6
74	A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6629-6629.	0.8	2
75	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. <i>Blood</i> , 2011, 118, 2845-2845.	0.6	0
76	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 735-735.	0.6	0
77	Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy. <i>Current Pharmaceutical Design</i> , 2010, 16, 3007-3014.	0.9	35
78	Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	0.6	87
79	Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. <i>Intensive Care Medicine</i> , 2010, 36, 1666-1674.	3.9	152
80	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2803-2815.	1.6	228
81	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010, 116, 1371-1371.	0.6	2
82	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010, 116, 2462-2462.	0.6	17
83	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. <i>Blood</i> , 2010, 116, 2471-2471.	0.6	2
84	Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 917-917.	0.6	0
85	Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010, 116, 1254-1254.	0.6	5
86	The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. <i>Blood</i> , 2010, 116, 3602-3602.	0.6	0
87	IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. <i>Blood</i> , 2010, 116, 2431-2431.	0.6	0
88	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. <i>Experimental Hematology</i> , 2009, 37, 728-738.	0.2	10
89	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 1062-1072.	3.3	97
90	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. <i>Blood</i> , 2009, 114, 2333-2333.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. <i>Clinical and Experimental Immunology</i> , 2008, 79, 100-104.	1.1	23
92	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. <i>Blood</i> , 2008, 111, 2765-2775.	0.6	239
93	Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study. <i>Blood</i> , 2008, 112, 3167-3167.	0.6	2
94	Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter's Syndrome Transformation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 1052-1052.	0.6	0
95	Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 5348-5354.	3.2	26
96	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	13.9	479
97	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 ⁺ into CD25 ⁺ T regulatory cells. <i>Blood</i> , 2007, 109, 2871-2877.	0.6	357
98	Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. <i>Blood</i> , 2007, 110, 921-927.	0.6	98
99	Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. <i>Leukemia</i> , 2007, 21, 353-355.	3.3	99
100	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class II-restricted peptides. <i>British Journal of Haematology</i> , 2007, 139, 415-424.	1.2	58
101	Quantitative Molecular Expression of the Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia Cells as a Possible Marker for Minimal Residual Disease Detection. <i>Blood</i> , 2007, 110, 4229-4229.	0.6	0
102	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 475-477.	1.4	22
103	Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. <i>European Journal of Haematology</i> , 2006, 76, 342-347.	1.1	29
104	Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase. <i>Blood</i> , 2006, 108, 1899-1899.	0.6	0
105	Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. <i>Haematologica</i> , 2006, 91, 941-8.	1.7	19
106	Effector T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. <i>Leukemia</i> , 2005, 19, 664-670.	3.3	119
107	Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. <i>European Journal of Immunology</i> , 2005, 35, 1155-1163.	1.6	45
108	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1438-1445.	1.8	61

#	ARTICLE	IF	CITATIONS
109	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. <i>Leukemia</i> , 2004, 18, 139-145.	3.3	63
110	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m ²). <i>Leukemia</i> , 2004, 18, 133-138.	3.3	30
111	New drugs for treatment of multiple myeloma. <i>Lancet Oncology</i> , The, 2004, 5, 430-442.	5.1	59
112	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. <i>Blood</i> , 2004, 104, 3052-3057.	0.6	305
113	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004, 89, 717-41.	1.7	48
114	Behavioral disturbances in the Alzheimer's care units: A six-months observation. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 245-252.	1.4	2
115	Risk factors for dementia of Alzheimer's type: A case-control, retrospective evaluation. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 253-259.	1.4	7
116	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. <i>British Journal of Haematology</i> , 2001, 113, 1051-1059.	1.2	48
117	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 46-53.	1.2	16
118	Idiotype Vaccination of Myeloma Patients After Chemotherapy. <i>Acta Oncologica</i> , 2000, 39, 807-808.	0.8	3
119	Antitumor vaccination: where we stand. <i>Haematologica</i> , 2000, 85, 1172-206.	1.7	53
120	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. <i>Blood</i> , 1999, 94, 673-683.	0.6	127
121	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. <i>Blood</i> , 1999, 94, 673-683.	0.6	2
122	Idiotypic vaccination as therapy for multiple myeloma. <i>Seminars in Hematology</i> , 1999, 36, 34-7.	1.8	7
123	CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. <i>Journal of Immunology</i> , 1999, 162, 6238-46.	0.4	4
124	Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. <i>Blood</i> , 1999, 94, 673-83.	0.6	36
125	Idiotypic vaccination in B-cell malignancies. <i>Trends in Molecular Medicine</i> , 1997, 3, 435-441.	2.6	12
126	DISTRIBUTION OF T CELL SIGNALING MOLECULES IN HUMAN MYELOMA. <i>British Journal of Haematology</i> , 1997, 97, 810-814.	1.2	100

#	ARTICLE	IF	CITATIONS
127	Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. <i>Blood</i> , 1997, 89, 212-8.	0.6	11
128	Clinical and Immunological Studies in Advanced Cancer Patients Sequentially Treated with Anti CD3 Monoclonal Antibody (OKT3) and Interleukin-2. <i>Leukemia and Lymphoma</i> , 1996, 21, 325-330.	0.6	7
129	Selective induction of CD73 expression in human lymphocytes by CD38 ligation: a novel pathway linking signal transducers with ecto-enzyme activities. <i>Journal of Immunology</i> , 1996, 157, 4354-62.	0.4	25
130	CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+ cells. <i>British Journal of Haematology</i> , 1995, 90, 625-632.	1.2	9
131	Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. <i>Blood</i> , 1995, 85, 3679-3687.	0.6	66
132	Reversible Bronchial Hyperresponsiveness Induced by OK-T3/IL-2 Administration in a Patient with Multiple Myeloma. <i>Respiration</i> , 1995, 62, 228-231.	1.2	0
133	T Cells in Multiple Myeloma: Is This a Reliable Population to Count on as Antitumor Effector Cells?. <i>Leukemia and Lymphoma</i> , 1995, 17, 63-70.	0.6	6
134	Usefulness of frequency analysis of cytotoxic T-lymphocytes precursors (CTL-p) for selection of HLA matched unrelated marrow donors. <i>Panminerva Medica</i> , 1995, 37, 168-70.	0.2	1
135	Correlation between disease activity and T-cell CD3 chain expression in a B-cell lymphoma. <i>British Journal of Haematology</i> , 1994, 88, 886-888.	1.2	33
136	Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. <i>British Journal of Haematology</i> , 1994, 87, 494-502.	1.2	5
137	Serum levels of tumour necrosis factor- α in patients with B-cell chronic lymphocytic leukaemia. <i>European Journal of Cancer</i> , 1994, 30, 1259-1263.	1.3	43
138	Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. <i>Blood</i> , 1993, 82, 1787-1797.	0.6	35
139	Cyclosporin A and dipyridamole: An effective combination against the generation of cytotoxic T lymphocytes (CTL). <i>Pharmacological Research</i> , 1992, 26, 12-13.	3.1	0
140	Constitutive production of tumor necrosis factor-alpha in hairy cell leukemia: possible role in the pathogenesis of the cytopenia(s) and effect of treatment with interferon-alpha. <i>Journal of Clinical Oncology</i> , 1992, 10, 954-959.	0.8	29
141	Sequential administration of OKT3 (anti-CD3) and interleukin-2 in two patients with chemoresistant hematological disease. <i>European Journal of Haematology</i> , 1992, 49, 150-152.	1.1	3
142	Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex [see comments]. <i>Blood</i> , 1991, 78, 1770-1780.	0.6	43
143	Difference in Polyamine Transport in Human B and T Lymphocytes. <i>Biological Chemistry Hoppe-Seyler</i> , 1991, 372, 75-78.	1.4	3
144	Dipyridamole in vitro suppresses the generation of T cell cytotoxic functions: Synergistic activity with cyclosporine. <i>European Journal of Haematology</i> , 1991, 46, 6-10.	1.1	2

#	ARTICLE	IF	CITATIONS
145	Amplification of T Cell Activation Induced by CD73 (Ecto-5'Nucleotidase) Engagement. <i>Advances in Experimental Medicine and Biology</i> , 1991, 309B, 155-158.	0.8	6
146	Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass. <i>Haematologica</i> , 1991, 76, 383-8.	1.7	4
147	Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5' nucleotidase (CD73).. <i>Tissue Antigens</i> , 1990, 35, 9-19.	1.0	120
148	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. <i>Blood</i> , 1990, 76, 393-400.	0.6	119
149	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. <i>Blood</i> , 1990, 76, 393-400.	0.6	124
150	Human T cell activation. Synergy between CD73 (ecto-5'-nucleotidase) and signals delivered through CD3 and CD2 molecules. <i>Journal of Immunology</i> , 1990, 145, 1664-74.	0.4	51
151	Multiple myeloma: altered CD4/CD8 ratio in bone marrow. <i>Haematologica</i> , 1990, 75, 129-31.	1.7	8
152	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. <i>Blood</i> , 1990, 76, 393-400.	0.6	40
153	Multiple Myeloma: Beta-2-Microglobulin is not a Useful Follow-Up Parameter. <i>Acta Haematologica</i> , 1989, 82, 122-125.	0.7	18
154	Monoclonal Immunoglobulin Gene Rearrangement in Peripheral Lymphocytes of a Patient with Multiple Myeloma. <i>Tumori</i> , 1989, 75, 1-3.	0.6	4
155	Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.. <i>Journal of Clinical Oncology</i> , 1989, 7, 119-125.	0.8	72
156	CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. <i>European Journal of Immunology</i> , 1989, 19, 1037-1044.	1.6	46
157	B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. <i>Journal of Clinical Immunology</i> , 1989, 9, 329-337.	2.0	4
158	Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology. <i>European Journal of Haematology</i> , 1989, 43, 30-34.	1.1	2
159	The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. <i>Blood</i> , 1989, 73, 1020-1027.	0.6	54
160	Altered expression of growth-regulated protooncogenes in human malignant plasma cells. <i>Cancer Research</i> , 1989, 49, 4701-4.	0.4	14
161	Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. <i>Tumori</i> , 1989, 75, 1-3.	0.6	0
162	The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. <i>Blood</i> , 1989, 73, 1020-7.	0.6	12

#	ARTICLE	IF	CITATIONS
163	Immune dysregulation in monoclonal gammopathies. Bone Marrow Transplantation, 1989, 4 Suppl 1, 165-7.	1.3	0
164	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	0.6	48
165	Human myeloma: Several subsets of circulating lymphocytes express plasma cell-associated antigens. European Journal of Haematology, 1988, 40, 299-304.	1.1	28
166	Biochemical and immunologic abnormalities in peripheral blood T lymphocytes of patients with hemophilia A. European Journal of Haematology, 1988, 41, 334-340.	1.1	5
167	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	0.6	44
168	Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clinical and Experimental Immunology, 1988, 73, 214-8.	1.1	30
169	The generation of alloreactive cytotoxic T lymphocytes requires the expression of ecto-5' nucleotidase activity. Journal of Immunology, 1988, 141, 3768-75.	0.4	15
170	Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5' nucleotidase deficiency. Journal of Clinical & Laboratory Immunology, 1988, 26, 89-95.	0.1	5
171	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-8.	0.6	8
172	Cytobiological Studies in Multiple Myeloma. Acta Haematologica, 1987, 78, 41-42.	0.7	2
173	Lack of Correlation between Plasma Cell Thymidine Labelling Index and Serum Beta-2-Microglobulin in Monoclonal Gammopathies. Acta Haematologica, 1987, 78, 239-242.	0.7	17
174	Immunologic and virologic findings in hemophiliacs do not correlate with ecto-5' nucleotidase activity of peripheral blood lymphocytes. A difference with homosexual men. European Journal of Haematology, 1987, 38, 310-314.	1.1	2
175	Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. Clinical and Experimental Immunology, 1987, 69, 426-32.	1.1	14
176	Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. Alabama Journal of Medical Sciences, 1987, 24, 400-4.	0.1	1
177	Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. Haematologica, 1987, 72, 171-5.	1.7	13
178	Differential expression of ecto-5' nucleotidase activity by functionally and phenotypically distinct subpopulations of human Leu-2+/T8+ lymphocytes. Journal of Immunology, 1986, 137, 484-9.	0.4	21
179	Decreased ecto-5' nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. Blood, 1985, 65, 530-534.	0.6	11
180	Decreased ecto-5' nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. Blood, 1985, 65, 530-4.	0.6	3

#	ARTICLE	IF	CITATIONS
181	Soluble factor(s) released by Concanavalin A activated lymph node lymphocytes induce proliferation and maturation of chronic lymphocytic leukaemia (CLL) B lymphocytes. <i>Journal of Clinical & Laboratory Immunology</i> , 1984, 13, 85-8.	0.1	1
182	Kinetics of circulating B lymphocytes in human myeloma. <i>Blood</i> , 1983, 61, 812-814.	0.6	35
183	Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. <i>British Journal of Haematology</i> , 1983, 54, 451-457.	1.2	5
184	Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. <i>British Journal of Haematology</i> , 1983, 54, 451-457.	1.2	16
185	The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. <i>Clinical and Experimental Immunology</i> , 1983, 51, 173-7.	1.1	23
186	Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA). <i>Journal of Clinical & Laboratory Immunology</i> , 1983, 12, 57-61.	0.1	1
187	5'-nucleotidase, adenosine deaminase and purine nucleoside phosphorylase activities in acute leukaemia. <i>Leukemia Research</i> , 1982, 6, 475-482.	0.4	38
188	Enzymes of purine metabolism in human peripheral lymphocyte subpopulations. <i>Clinical and Experimental Immunology</i> , 1982, 50, 148-54.	1.1	44
189	Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes. <i>Journal of Immunology</i> , 1982, 129, 1430-5.	0.4	75